Drug Type Monoclonal antibody |
Synonyms GR-1802, GR1802 |
Target |
Mechanism IL-4Rα inhibitors(Interleukin-4 receptor subunit alpha inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Dermatitis, Atopic | Phase 3 | CN | 16 Jan 2024 | |
Rhinitis, Allergic, Seasonal | Phase 2 | - | 01 Mar 2024 | |
Chronic Urticaria | Phase 2 | CN | 07 Apr 2023 | |
Chronic rhinosinusitis with nasal polyps | Phase 2 | CN | 08 Feb 2023 | |
Asthma | Phase 2 | CN | 06 Jun 2022 |